Abstract:
A method, computer program, and computer system is provided for fault detection in an electrical network. An inductance between a reference point and a fault is determined at a first time based on measuring a fault current. A resistance between the reference point and the fault may be determined at a second time based on measuring a differential of the fault current as zero. A location of the fault may be identified based on the inductance and the resistance.
Abstract:
C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) provides therapeutic effects in motor impairments associated with Parkinson disease (PD), and provides long lasting antidepressant effects, thus useful in treating and mitigating depression, particularly PD-depression co-morbid condition. A method for treating or mitigating depression, including administrating an effective amount of C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) to a subject in need thereof. A method for treating or mitigating motor impairments associated with Parkinson's disease (PD), including administrating an effective amount of C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) to a subject in need thereof.
Abstract:
Covalently cross-linked copolymers are described herein. More specifically, polysaccharide-polyamine copolymeric matrices or structures and cationic copolymeric matrices are described herein. The polysaccharide-polyamine copolymers, when protonated, can form cationic copolymeric matrices having exceptionally high densities of cationic sites. In one form, the covalently cross-linked copolymers provide a three-dimensional structure, especially when hydrated.
Abstract:
This disclosure relates to compounds and methods of treating or preventing a Nox related disease or condition comprising administering to a subject in need thereof a Nox inhibitor or pharmaceutical compositions comprising a Nox inhibitor disclosed herein, derivatives, or compounds disclosed herein optionally substituted with one or more substitutes including optional salt and prodrug forms. In certain embodiments, this disclosure relates to sulfonylurea compounds and uses reported herein.
Abstract:
A method, apparatus and kit have been discovered which utilize pulsed odorants, drugs, medicaments, and combinations thereof to treat diseases, symptoms of diseases and the like. In one form, the pulsed odorants, drugs, medicaments, and combinations thereof can be used to regenerate the connections of the neurons of the brain and central nervous system in the treatment of symptoms of such person afflicted with neuro-disorders, such as caused by disease or trauma.
Abstract:
A majorize-minimize (MM) mathematical principle is applied to least squares regularization estimation problems to effect efficient processing of image data sets to provide good quality images. In a ground penetrating radar application, these approaches can reduce processing time and memory use by accounting for a symmetric nature of a given radar pulse, accounting for similar discrete time delays between transmission of a given radar pulse and reception of reflections from the given radar pulse, and accounting for a short duration of the given radar pulse.
Abstract:
The present invention is directed to a crosslinked or non-crosslinked polymer particle, wherein the crosslinked polymer particle comprises a copolymer of poly(alklyene glycol-graft-lactate) that is crosslinked by at least one hydrolysable monomer. Another embodiment of the present invention is a polymer particle comprising a crosslinked polymer particle that is a product of starting materials comprising (a) a hydrophilic monomer, (b) a hydrophobic monomer, and (c) a hydrolysable crosslinking agent. Another embodiment of the present invention is a polymer particle comprising, a crosslinked copolymer comprises structures represented by Formulas (I), (II), and (III), where Formulas (I), (II) and (III) are defined in the specification. Yet other embodiments of the present invention include a method of preparing a methacrylate terminated macromonomer, a method of preparing a crosslinking agent, and a method of preparing a therapeutic agent loaded nanosphere by dispersion polymerization.
Abstract:
A myocardial blood flow analysis scan includes incorporating a pharmacological kinetic model with the standard factor analysis model where each time activity curve is assumed to be a linear combination of factor curves. Pharmacological kinetics based factor analysis of dynamic structures (K-FADS-II) model can be applied, whereby estimating factor curves in the myocardium can be physiologically meaningful is provided. Additional optional aspects include performing a discretization to transform continuous-time K-FADS-II model into a discrete-time K-FADS-II model and application of an iterative Improved Voxel-Resolution myocardial blood flow (IV-MBF) algorithm. Where the model is applied without assumption that a right ventricle tissue curve and a left ventricle tissue curve obey a particular mathematical relationship, a least squares objective function can be applied to obtain estimates for parameters of the pharmacological kinetic model by applying a majorize-minimize optimization technique to iteratively estimate the curves.
Abstract:
The mathematical majorize-minimize principle is applied in various ways to process the image data to provide a more reliable image from the backscatter data using a reduced amount of memory and processing resources. A processing device processes the data set by creating an estimated image value for each voxel in the image by iteratively deriving the estimated image value through application of a majorize-minimize principle to solve a maximum a posteriori (MAP) estimation problem associated with a mathematical model of image data from the data. A prior probability density function for the unknown reflection coefficients is used to apply an assumption that a majority of the reflection coefficients are small. The described prior probability density functions promote sparse solutions automatically estimated from the observed data.
Abstract:
Inhibitors of protein phosphatase-1 (PP-1) and their use in a method for the treatment or prevention of viral infections caused by HIV or ebola virus are disclosed. Inhibitors of protein phosphatase-1 in effective amounts have been shown to slow down viral replication upon contacting ebola virus or cells containing the ebola virus.